<DOC>
	<DOCNO>NCT02318602</DOCNO>
	<brief_summary>This multicenter , open-label trial ass long-term safety efficacy Cannabidiol Oral Solution adjunctive therapy pediatric adult subject treatment-resistant seizure disorder , include Lennox-Gastaut syndrome ( LGS ) Dravet syndrome ( DS ) . All participant roll previous trial : INS011-14-029 ( NCT02324673 ) , INS011-14-024 ( NCT02318537 ) , INS011- 14-025 ( NCT02318563 ) .</brief_summary>
	<brief_title>Cannabidiol Oral Solution Adjunctive Treatment Treatment-resistant Seizure Disorder</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Completed scheduled visit treatment phase core study Informed consent/assent ( applicable ) voluntarily provide participant and/or parent ( ) /caregiver ( ) accordance applicable law , regulation , local requirement Is medically stable anticipate change chronic medication Continues meet protocolspecified criterion qualification contraception , include treatmentresistant seizure disorder In opinion Investigator , subject and/or parent ( ) /caregiver ( ) able continue keep accurate seizure diary Inadequate supervision parent ( ) /caregiver ( ) History current use dietary supplement , drug overthe counter medication outside protocolspecified parameter Signs , symptoms history condition , per protocol opinion investigator , might compromise : 1. safety wellbeing participant study staff 2. safety wellbeing participant 's offspring ( pregnancy breastfeed ) 3. analysis result</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Lennox-Gastaut syndrome</keyword>
	<keyword>Dravet syndrome</keyword>
	<keyword>Treatment-resistant seizure</keyword>
</DOC>